Table 1 Characteristics of the eligible studies
Study | Year | Inclusion period | Register | Region/ Country | Phase | Group | No.patients | No.male | Mean Age (range, year) | Stage | AJCC | Median follow-up (years) | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fountzilas [8] | 2012 | 2003–2008 | ACTRN 12609000730202 | Europe | II | IC + CCRT CCRT | 72 69 | 55 48 | 49 (19–82) 51 (15–79) | IIb-IVb | 6th | 4.6 | 4 |
Tan [9] | 2015 | 2004–2012 | CDR0000657121 | Singapore | II/III | IC + CCRT CCRT | 86 86 | 71 63 | 49 (42–55) 52 (44–57) | III-IVb | 5th | 3.4 3.2 | 3 |
Sun [10]/ Li [11] | 2016/2019 | 2011–2013 | NCT01245959 | China | III | IC + CCRT CCRT | 241 239 | 193 174 | 42 (36–49) 44 (39–50) | III-IVb | 7th | 6 | 3 |
Cao [12]/ Yang [13] | 2017/2019 | 2008–2015 | NCT00705627 | China | III | IC + CCRT CCRT | 238 238 | 173 190 | 44 (19–65)42 (21–66) | III-IVb | 6th | 6.9 | 3 |
Frikha [14] | 2018 | 2009–2012 | NCT00828386 | France/ Tunisia | III | IC + CCRT CCRT | 42 41 | 28 32 | 46 48 | T2b, T3, T4 and/or N1-N3, M0 | NR | 3.6 | 3 |
Hong [15] | 2018 | 2003–2009 | NCT00201396 | China | III | IC + CCRT CCRT | 239 240 | 176 179 | 45 (15–69) 47 (19–70) | IVa-IVb | 5th | 6 | 3 |
Zhang [16] | 2019 | 2013–2016 | NCT01872962 | China | III | IC + CCRT CCRT | 242 238 | 182 164 | 46 (18–64) 45 (20–64) | III-IVb | 7th | 3.6 | 3 |